PATENT CLAIM ANALYSIS

Application Number: 15984067
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "480000"]

Abstract:
Provided herein are therapies including dosage regimens for the treatment of cancer using B-RAF and an immune checkpoint inhibitor in combination with and/or without a MEK inhibitor.

Claim (Index 33):
The method of  claim 32 , wherein the melanoma is unresectable or metastatic melanoma.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 93.0
- Lexical Diversity: 1.03704
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15116712', '15227792', '15852125', '15943229', '14893746']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.779578023370333
- 35 USC 102 Novelty (BERT): 0.5086974246376811
- Combined Prediction Score: 0.7524899634970678
- Mean Citation Score: 264.939158
- Max Citation Score: 273.79593
- Similarity Product: 198.35562082221333

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test